Bruker’s (BRKR) “Neutral” Rating Reiterated at JPMorgan Chase & Co.

Bruker (NASDAQ:BRKR)‘s stock had its “neutral” rating restated by JPMorgan Chase & Co. in a research report issued on Wednesday, Benzinga reports. They currently have a $60.00 target price on the medical research company’s stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 6.78% from the stock’s previous close.

Other equities analysts also recently issued reports about the company. Barclays raised their price objective on Bruker from $58.00 to $70.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a report on Monday, August 31st. TD Cowen upped their target price on Bruker from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday. Zacks Research downgraded shares of Bruker from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 2nd. Finally, UBS Group began coverage on shares of Bruker in a research report on Wednesday, September 9th. They set a “neutral” rating and a $65.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $59.43.

Bruker Trading Down 0.1%

BRKR opened at $56.19 on Wednesday. The company’s 50 day moving average is $58.59 and its 200-day moving average is $53.04. Bruker has a 1-year low of $32.37 and a 1-year high of $66.98. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76. The company has a market cap of $8.56 billion, a P/E ratio of -80.27, a PEG ratio of 1.72 and a beta of 1.22.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.11. The business had revenue of $838.50 million for the quarter, compared to analyst estimates of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%. Bruker’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities research analysts predict that Bruker will post 2.12 earnings per share for the current fiscal year.

Insider Activity at Bruker

In related news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total transaction of $105,740.00. Following the completion of the sale, the vice president owned 134,806 shares of the company’s stock, valued at $7,127,193.22. This trade represents a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 27.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Bruker

Several institutional investors have recently added to or reduced their stakes in BRKR. Sivik Global Healthcare LLC bought a new position in shares of Bruker during the 3rd quarter worth approximately $4,209,000. GAMMA Investing LLC grew its position in shares of Bruker by 13.0% during the 3rd quarter. GAMMA Investing LLC now owns 5,373 shares of the medical research company’s stock worth $348,000 after buying an additional 618 shares during the period. Moody National Bank Trust Division bought a new stake in shares of Bruker in the 3rd quarter valued at $728,000. Sequoia Financial Advisors LLC bought a new stake in shares of Bruker in the 2nd quarter valued at $250,000. Finally, Tidal Investments LLC increased its stake in shares of Bruker by 180.4% in the 2nd quarter. Tidal Investments LLC now owns 29,092 shares of the medical research company’s stock valued at $1,751,000 after acquiring an additional 18,715 shares in the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, chemicals, biological samples and industrial products. Its customers include academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, environmental laboratories and industrial manufacturers.

The company’s portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray instruments, microscopy and surface-analysis platforms, molecular spectroscopy systems, and analytical tools for proteomics, spatial biology, metabolomics and materials research.